Merck returning rights to heart drug vernakalant to Cardiome Pharma

VANCOUVER – Cardiome Pharma Corp. (TSX:COM) said Wednesday that Merck is returning the global marketing and development rights for both the intravenous and oral formulations for vernakalant.

News from © The Canadian Press, . All rights reserved.
This material may not be published, broadcast, rewritten or redistributed.

The Canadian Press

The Canadian Press is Canada's trusted news source and leader in providing real-time, bilingual multimedia stories across print, broadcast and digital platforms.